SNSE / Sensei Biotherapeutics, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5

Sensei Biotherapeutics, Inc.

Insideraktier666.731 shares
Total Insiders22
Insider-stemningsscore

Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.

Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.

Officers sentiment score

Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.

Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.

Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.

Nøgle Insider Metrics

Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.

For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).

Netto antal insidere, der køber (rang)

-2 ( )
9923 out of 10951

Netto antal insidere, der køber, er det samlede antal insiders, der køber minus det samlede antal insiders, der har solgt inden for de sidste 90 dage. Percentilrangen vises her (spænder fra 0 til 100%).

Procent af float købt af insidere (rangering)

N/A

Procent af float købt af insidere er det samlede antal aktier købt af insidere minus det samlede antal aktier solgt af insidere inden for de sidste 90 dage, divideret med den samlede float og ganget med 100.

Insiderhandelsdiagram

Sensei Biotherapeutics, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.

Insiderliste og lønsomhedsmålinger

Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.

See our leaderboard of most profitable insider traders.

Insider Gennemsnitlig fortjeneste (%) Aktier
Ejet
Dele
Justeret
Apeiron Investment Group Ltd. 10% Owner - [10%] 0 0
Samuel Broder Director - [D] 8.932 447
Cambrian BioPharma Inc 10% Owner - [10%] 130.142 130.142
John Celebi PRESIDENT AND CEO, Director - [D] [O] 105.862 5.293
Erin Colgan CHIEF FINANCIAL OFFICER - [O] 67.462 3.373
Jessie English Director - [D] 8.932 447
Patrick Stephen Gallagher Chief Business Officer - [O] 34.130 1.706
Insider Gennemsnitlig fortjeneste (%) Aktier
Ejet
Dele
Justeret
Christopher Gerry President & PEO - [O] 1.574 1.574
H&s Investments I Lp 10% Owner - [10%] 4.425.998 221.300
H&s Ventures Llc 10% Owner - [10%] 4.425.998 221.300
Bob Holmen Director - [D] 25.598 1.280
Kristian Humer Director - [D] 8.932 447
Millennium Management Llc 10% Owner - [10%] 147.731 147.731
James Peyer 10% Owner - [10%] 130.142 130.142
Insider Gennemsnitlig fortjeneste (%) Aktier
Ejet
Dele
Justeret
Robert Hamilton Pierce Chief R&D Officer - [O] 21.000 1.050
Thomas G Ricks Director - [D] 343.863 17.193
William R Ringo Director - [D] 23.399 1.170
Henry Samueli 10% Owner - [10%] 4.425.998 221.300
Susan Samueli 10% Owner - [10%] 4.425.998 221.300
Michael Schulman 10% Owner - [10%] 4.425.998 221.300
Deneen Vojta Director - [D] 8.932 447
der Horst Edward van CHIEF SCIENTIFIC OFFICER - [O] 59.794 2.990

Report errors via our new Insider Auditing Tool

Track Records af insiderkøb - Kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i SNSE / Sensei Biotherapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2026-04-07 MILLENNIUM MANAGEMENT LLC 1.108 33,3800 1.108 33,3800 36.985 16 32.6200 -842 -2,28
2026-04-06 MILLENNIUM MANAGEMENT LLC 1.104 31,0200 1.104 31,0200 34.246
2026-04-02 MILLENNIUM MANAGEMENT LLC 701 35,5472 701 35,5472 24.919
2026-04-02 MILLENNIUM MANAGEMENT LLC 1.276 34,7524 1.276 34,7524 44.344
2026-04-02 MILLENNIUM MANAGEMENT LLC 26 33,4704 26 33,4704 870
2026-04-01 MILLENNIUM MANAGEMENT LLC 3.401 35,4554 3.401 35,4554 120.584
2026-04-01 MILLENNIUM MANAGEMENT LLC 1.613 34,5863 1.613 34,5863 55.788
2026-04-01 MILLENNIUM MANAGEMENT LLC 1.161 31,5309 1.161 31,5309 36.607
2026-03-31 MILLENNIUM MANAGEMENT LLC 411 32,5962 411 32,5962 13.397

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SNSE / Sensei Biotherapeutics, Inc. Insider Trades
Track Records af insidersalg - Kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i SNSE / Sensei Biotherapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2026-06-01 Peyer James 476 21,1400 476 21,1400 10.063 2 15.8450 -2.520 -25,04
2026-06-01 Peyer James 24.524 20,0000 24.524 20,0000 490.480
2026-06-01 Cambrian BioPharma Inc 476 21,1400 476 21,1400 10.063
2026-06-01 Cambrian BioPharma Inc 24.524 20,0000 24.524 20,0000 490.480
2026-04-07 MILLENNIUM MANAGEMENT LLC 1.108 33,3800 1.108 33,3800 36.985
2026-04-07 MILLENNIUM MANAGEMENT LLC 300 32,2467 300 32,2467 9.674
2026-04-07 MILLENNIUM MANAGEMENT LLC 4.423 31,3843 4.423 31,3843 138.813
2026-04-07 MILLENNIUM MANAGEMENT LLC 205 29,7146 205 29,7146 6.091
2026-04-07 MILLENNIUM MANAGEMENT LLC 2.115 28,9417 2.115 28,9417 61.212

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SNSE / Sensei Biotherapeutics, Inc. Insider Trades
Transaktionshistorik

Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.

Fil
Dato
Handle
Dato
Form Insider Ticker Sikkerhedstitel Kode 10b5-1 Direkte Dyrke motion
Pris
Enhed
Pris
Enheder
Ændret
Værdi
Ændret (1K)
Tilbage
Muligheder
Tilbage
Aktier
2026-06-01 2026-06-01 4 Peyer James SNSE Common Stock S - Sale D 21,1400 -476 -10 130.142
2026-06-01 2026-06-01 4 Peyer James SNSE Common Stock S - Sale D 20,0000 -24.524 -490 130.618
2026-06-01 2026-06-01 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 21,1400 -476 -10 130.142
2026-06-01 2026-06-01 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 20,0000 -24.524 -490 130.618
2026-05-15 2026-04-07 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 33,3800 -1.108 -37 133.986
2026-05-15 2026-04-07 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 32,2467 -300 -10 133.986
2026-05-15 2026-04-07 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 31,3843 -4.423 -139 133.986
2026-05-15 2026-04-07 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 29,7146 -205 -6 133.986
2026-05-15 2026-04-07 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 28,9417 -2.115 -61 133.986
2026-05-15 2026-04-07 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 33,3800 1.108 37 133.986
2026-05-15 2026-04-06 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 31,9628 -45 -1 141.029
2026-05-15 2026-04-06 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 31,0227 -1.214 -38 141.029
2026-05-15 2026-04-06 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 31,0200 1.104 34 141.029
2026-05-15 2026-04-02 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 34,8007 -1.134 -39 144.974
2026-05-15 2026-04-02 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 33,3470 -374 -12 144.974
2026-05-15 2026-04-02 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 32,6041 -1.794 -58 144.974
2026-05-15 2026-04-02 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 31,7510 -1.265 -40 144.974
2026-05-15 2026-04-02 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 30,8638 -3.099 -96 144.974
2026-05-15 2026-04-02 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 35,5472 701 25 144.974
2026-05-15 2026-04-02 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 34,7524 1.276 44 144.974
2026-05-15 2026-04-02 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 33,4704 26 1 144.974
2026-05-15 3 MILLENNIUM MANAGEMENT LLC SNSE Common Stock I 127.095
2026-05-15 2026-03-30 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 27,6800 -370 -10 145.678
2026-05-15 2026-03-30 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 25,8501 -518 -13 145.678
2026-05-15 2026-03-30 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 27,6800 370 10 145.678
2026-05-15 2026-03-30 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 26,7000 1.176 31 145.678
2026-05-15 2026-03-30 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 25,9900 4.995 130 145.678
2026-05-15 2026-03-30 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 25,0784 2.992 75 145.678
2026-05-15 2026-03-27 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 27,3690 -36 -1 142.360
2026-05-15 2026-03-27 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 26,7652 -469 -13 142.360
2026-05-15 2026-03-27 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 28,1301 294 8 142.360
2026-05-15 2026-03-27 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 27,2826 4.384 120 142.360
2026-05-15 2026-03-27 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 26,2933 10.643 280 142.360
2026-05-15 2026-03-26 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 28,6882 -1.274 -37 131.370
2026-05-15 2026-03-26 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 26,8797 -583 -16 131.370
2026-05-15 2026-03-26 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 29,9788 1.025 31 131.370
2026-05-15 2026-03-26 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 28,8539 2.601 75 131.370
2026-05-15 2026-03-26 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 27,9467 1.327 37 131.370
2026-05-15 2026-03-26 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 27,2267 778 21 131.370
2026-05-15 2026-04-01 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 34,7464 -46 -2 147.731
2026-05-15 2026-04-01 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 31,5200 -1.104 -35 147.731
2026-05-15 2026-04-01 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 35,4554 3.401 121 147.731
2026-05-15 2026-04-01 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 34,5863 1.613 56 147.731
2026-05-15 2026-04-01 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 31,5309 1.161 37 147.731
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 31,5200 -87 -3 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 28,4050 -5 -0 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 27,1147 -57 -2 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 25,1676 -1.251 -31 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock S - Sale I 24,2843 -191 -5 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 32,5962 411 13 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 31,4512 1.957 62 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 30,4754 186 6 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 27,7838 17 0 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 26,7259 1.048 28 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 25,3209 1.770 45 146.657
2026-05-15 2026-03-31 4 MILLENNIUM MANAGEMENT LLC SNSE Common Stock P - Purchase I 24,6857 616 15 146.657
2025-12-10 2025-12-09 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 7,9200 -446 -4 155.142
2025-12-10 2025-12-09 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 8,0400 -395 -3 155.588
2025-12-10 2025-12-09 4 Cambrian BioPharma Inc SNSE Common Stock M - Exercise D 6,4000 395 3 155.983
2025-12-10 2025-12-09 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 7,9500 -2.666 -21 155.588
2025-12-10 2025-12-09 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 8,5900 -3.105 -27 158.254
2025-12-10 2025-12-09 4 Peyer James SNSE Common Stock S - Sale I 7,9200 -446 -4 155.142
2025-12-10 2025-12-09 4 Peyer James SNSE Common Stock S - Sale I 8,0400 -395 -3 155.588
2025-12-10 2025-12-09 4 Peyer James SNSE Common Stock M - Exercise I 6,4000 395 3 155.983
2025-12-10 2025-12-09 4 Peyer James SNSE Common Stock S - Sale I 7,9500 -2.666 -21 155.588
2025-12-10 2025-12-08 4 Peyer James SNSE Common Stock S - Sale I 8,5900 -3.105 -27 158.254
2025-12-08 2025-12-05 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 13,1600 -42 -1 161.359
2025-12-08 2025-12-05 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 12,2900 -1.745 -21 161.401
2025-12-08 2025-12-05 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 11,4000 -14.508 -165 163.146
2025-12-08 2025-12-04 4 Cambrian BioPharma Inc SNSE Common Stock S - Sale D 9,0600 -5.000 -45 177.654
2025-12-08 2025-12-05 4 Peyer James SNSE Common Stock S - Sale I 13,1600 -42 -1 161.359
2025-12-08 2025-12-05 4 Peyer James SNSE Common Stock S - Sale I 12,2900 -1.745 -21 161.401
2025-12-08 2025-12-05 4 Peyer James SNSE Common Stock S - Sale I 11,4000 -14.508 -165 163.146
2025-12-08 2025-12-04 4 Peyer James SNSE Common Stock S - Sale I 9,0600 -5.000 -45 177.654
2025-11-24 3 Gerry Christopher SNSE Common Stock D 1.574
2025-02-26 2025-02-19 4 Celebi John SNSE Common Stock F - Taxes D 0,4760 -5.558 -3 105.862
2025-02-26 2025-02-19 4 van der Horst Edward SNSE Common Stock F - Taxes D 0,4760 -2.276 -1 59.794
2024-02-16 2024-02-15 4 van der Horst Edward SNSE Common Stock F - Taxes D 0,7900 -2.843 -2 56.070
2024-02-16 2024-02-15 4 Celebi John SNSE Common Stock F - Taxes D 0,7900 -5.891 -5 105.420
2024-02-16 2024-02-15 4 Colgan Erin SNSE Common Stock F - Taxes D 0,7900 -3.627 -3 67.462
2023-09-13 2023-09-11 4 Celebi John SNSE Common Stock P - Purchase D 0,8500 500 0 111.311
2023-09-11 2023-02-15 4 Gallagher Patrick Stephen SNSE Common Stock F - Taxes D 1,5000 -9.383 -14 34.130
2023-09-11 2023-02-15 4 Celebi John SNSE Common Stock F - Taxes D 1,5000 -20.492 -31 110.811
2023-09-11 2023-02-15 4 van der Horst Edward SNSE Common Stock F - Taxes D 1,5000 -9.525 -14 52.913
2023-09-11 2023-02-15 4 Colgan Erin SNSE Common Stock F - Taxes D 1,5000 -10.943 -16 68.089
2023-08-02 2023-07-31 4 Peyer James SNSE Common Stock D - Sale to Issuer I 1,2600 -1.587.302 -2.000 3.653.120
2023-08-02 2023-07-31 4 Cambrian BioPharma Inc SNSE Common Stock D - Sale to Issuer D 1,2600 -1.587.302 -2.000 3.653.120
2023-07-12 2023-07-10 4 RINGO WILLIAM R SNSE Common Stock A - Award D 4.466 23.399
2023-07-12 2023-07-10 4 RICKS THOMAS G SNSE Common Stock A - Award D 4.466 8.932
2023-07-12 2023-07-10 4 Broder Samuel SNSE Common Stock A - Award D 4.466 8.932
2023-07-12 2023-07-10 4 Humer Kristian SNSE Common Stock A - Award D 4.466 8.932
2023-07-12 2023-07-10 4 English Jessie SNSE Common Stock A - Award D 4.466 8.932
2023-07-12 2023-07-10 4 Holmen Bob SNSE Common Stock A - Award D 4.466 25.598
2023-07-12 2023-07-10 4 Vojta Deneen SNSE Common Stock A - Award D 4.466 8.932
2023-07-12 2023-07-10 4 Peyer James SNSE Common Stock A - Award I 4.466 5.240.422
2023-07-12 2023-07-10 4 Cambrian BioPharma Inc SNSE Common Stock A - Award D 4.466 5.240.422
2023-06-02 2023-06-01 4 Apeiron Investment Group Ltd. By Presight Sensei Co-Invest Fund, L.P. SNSE Common Stock S - Sale I 1,5800 -955.738 -1.510 0
2023-06-02 2023-06-01 4 Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. SNSE Common Stock S - Sale I 1,5800 -2.485.923 -3.928 0
2023-03-29 2023-02-15 4/A Gallagher Patrick Stephen SNSE Common Stock A - Award D 14.200 43.513
2023-03-29 2023-02-15 4/A Gallagher Patrick Stephen SNSE Common Stock A - Award D 29.313 29.313
2023-03-29 2023-02-15 4/A Celebi John SNSE Common Stock A - Award D 21.300 131.303
2023-03-29 2023-02-15 4/A Celebi John SNSE Common Stock A - Award D 51.893 110.003
2023-03-29 2023-02-15 4/A Colgan Erin SNSE Common Stock A - Award D 21.300 79.032
2023-03-29 2023-02-15 4/A Colgan Erin SNSE Common Stock A - Award D 30.046 57.732
2023-03-07 2022-06-10 4/A Cambrian BioPharma Inc SNSE Restricted Stock Unit Grant A - Award D 4.466 5.235.956
2023-02-27 2023-02-23 4 Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. SNSE Common Stock P - Purchase I 1,6023 1.100 2 2.485.923
2023-02-27 2023-02-23 4 Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. SNSE Common Stock P - Purchase I 1,6150 1.100 2 2.484.823
2023-02-17 2023-02-15 4 Celebi John SNSE Common Stock A - Award D 21.300 127.307
2023-02-17 2023-02-15 4 Celebi John SNSE Common Stock A - Award D 51.893 106.007
2023-02-17 2023-02-15 4 Gallagher Patrick Stephen SNSE Common Stock A - Award D 14.200 43.515
2023-02-17 2023-02-15 4 Gallagher Patrick Stephen SNSE Common Stock A - Award D 29.313 29.313
2023-02-17 2023-02-15 4 Colgan Erin SNSE Common Stock A - Award D 21.300 73.032
2023-02-17 2023-02-15 4 Colgan Erin SNSE Common Stock A - Award D 30.046 51.732
2023-02-17 2023-02-15 4 van der Horst Edward SNSE Common Stock A - Award D 17.700 62.438
2023-02-17 2023-02-15 4 van der Horst Edward SNSE Common Stock A - Award D 23.565 44.738
2022-12-16 3 van der Horst Edward SNSE Common Stock D 21.173
2022-08-01 2022-06-10 4/A Peyer James SNSE Restricted Stock Unit Grant A - Award I 4.466 5.235.956
2022-08-01 3/A Peyer James SNSE Common Stock I 2.282.827
2022-07-20 3 Presight Co-Invest Management, L.L.C. By Presight Sensei Co-Invest Fund, L.P. SNSE Common Stock I 955.738
2022-07-20 3 Presight Co-Invest Management, L.L.C. By Apeiron Investment Group Ltd. SNSE Common Stock I 2.483.723
2022-06-14 2022-06-10 4 Cambrian BioPharma Inc SNSE Restricted Stock Unit Grant A - Award D 4.466 5.235.954
2022-06-14 2022-06-10 4 Peyer James SNSE Restricted Stock Unit Grant A - Award I 4.466 5.235.954
2022-06-14 2022-06-10 4 Humer Kristian SNSE Common Stock A - Award D 4.466 4.466
2022-06-14 2022-06-10 4 Vojta Deneen SNSE Common Stock A - Award D 4.466 4.466
2022-06-14 2022-06-10 4 RICKS THOMAS G SNSE Common Stock A - Award D 4.466 4.466
2022-06-14 2022-06-10 4 English Jessie SNSE Common Stock A - Award D 4.466 4.466
2022-06-14 2022-06-10 4 Holmen Bob SNSE Common Stock A - Award D 4.466 21.132
2022-06-14 2022-06-10 4 Broder Samuel SNSE Common Stock A - Award D 4.466 4.466
2022-06-10 2022-03-02 4/A Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 3,2000 1.203 4 5.231.488
2022-06-10 2022-03-02 4/A Peyer James SNSE Common Stock P - Purchase I 3,2000 1.203 4 5.231.488
2022-04-21 2021-03-23 4/A Peyer James SNSE Common Stock P - Purchase I 14,3400 9.500 136 4.798.293
2022-04-21 2021-02-18 4/A Peyer James SNSE Common Stock P - Purchase I 19,7500 752 15 4.690.905
2022-04-21 2021-03-23 4/A Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 14,3400 9.500 136 4.798.293
2022-04-21 2021-02-18 4/A Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 19,7500 752 15 4.690.905
2022-03-09 2022-03-08 4 RINGO WILLIAM R SNSE Stock Option (Right to Buy) A - Award D 3,08 29.100 29.100
2022-03-09 2022-03-08 4 RINGO WILLIAM R SNSE Common Stock A - Award D 10.000 18.933
2022-03-09 2022-03-08 4 RINGO WILLIAM R SNSE Common Stock A - Award D 8.933 8.933
2022-03-02 2022-03-02 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 3,2000 1.203 4 5.231.989
2022-03-02 2022-03-02 4 Peyer James SNSE Common Stock P - Purchase I 3,2000 1.203 4 5.231.989
2022-03-01 2022-03-01 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 3,6000 2.458 9 5.230.786
2022-03-01 2022-02-28 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 3,6000 42 0 5.228.328
2022-03-01 2022-03-01 4 Peyer James SNSE Common Stock P - Purchase I 3,6000 2.458 9 5.230.786
2022-03-01 2022-02-28 4 Peyer James SNSE Common Stock P - Purchase I 3,6000 42 0 5.228.328
2022-02-28 2022-02-25 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 3,6500 2.500 9 5.228.286
2022-02-28 2022-02-25 4 Peyer James SNSE Common Stock P - Purchase I 3,6500 2.500 9 5.228.286
2022-02-24 2022-02-24 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 3,6300 15.000 54 5.225.786
2022-02-24 2022-02-23 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 3,8000 2.500 10 5.210.786
2022-02-24 2022-02-24 4 Peyer James SNSE Common Stock P - Purchase I 3,6300 15.000 54 5.225.786
2022-02-24 2022-02-23 4 Peyer James SNSE Common Stock P - Purchase I 3,8000 2.500 10 5.210.786
2022-02-22 2022-02-18 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 3,9700 15.000 60 5.208.286
2022-02-22 2022-02-17 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,1700 4.949 21 5.193.286
2022-02-22 2022-02-18 4 Peyer James SNSE Common Stock P - Purchase I 3,9700 15.000 60 5.208.286
2022-02-22 2022-02-17 4 Peyer James SNSE Common Stock P - Purchase I 4,1700 4.949 21 5.193.286
2022-02-17 2022-02-15 4 Pierce Robert Hamilton SNSE Stock Option (Right to Buy) A - Award D 4,30 62.000 62.000
2022-02-17 2022-02-15 4 Pierce Robert Hamilton SNSE Common Stock A - Award D 21.000 21.000
2022-02-17 2022-02-15 4 Colgan Erin SNSE Stock Option (Right to Buy) A - Award D 4,30 62.000 62.000
2022-02-17 2022-02-15 4 Colgan Erin SNSE Common Stock A - Award D 21.000 21.686
2022-02-17 2022-02-15 4 Celebi John SNSE Stock Option (Right to Buy) A - Award D 4,30 161.600 161.600
2022-02-17 2022-02-15 4 Celebi John SNSE Common Stock A - Award D 53.900 54.114
2022-02-16 2022-02-16 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,2500 2.551 11 5.188.337
2022-02-16 2022-02-14 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,1800 10.000 42 5.185.786
2022-02-16 2022-02-16 4 Peyer James SNSE Common Stock P - Purchase D 4,2500 2.551 11 5.188.337
2022-02-16 2022-02-14 4 Peyer James SNSE Common Stock P - Purchase I 4,1800 10.000 42 5.185.786
2022-02-14 2022-02-11 4 Peyer James SNSE Common Stock P - Purchase I 4,4000 12.500 55 5.175.786
2022-02-14 2022-02-10 4 Peyer James SNSE Common Stock P - Purchase I 4,5800 5.000 23 5.163.286
2022-02-14 2022-02-11 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,4000 12.500 55 5.175.786
2022-02-14 2022-02-10 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,5800 5.000 23 5.163.286
2022-02-08 2022-02-08 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,3300 10.000 43 5.158.286
2022-02-08 2022-02-04 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,4500 2.500 11 5.148.286
2022-02-08 2022-02-03 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,6500 17.500 81 5.145.786
2022-02-08 2022-02-08 4 Peyer James SNSE Common Stock P - Purchase I 4,3300 10.000 43 5.158.286
2022-02-08 2022-02-04 4 Peyer James SNSE Common Stock P - Purchase I 4,4500 2.500 11 5.148.286
2022-02-08 2022-02-03 4 Peyer James SNSE Common Stock P - Purchase I 4,6500 17.500 81 5.145.786
2022-01-31 2022-01-28 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,2200 8.900 38 5.128.286
2022-01-31 2022-01-27 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,3100 6.100 26 5.119.386
2022-01-31 2022-01-28 4 Peyer James SNSE Common Stock P - Purchase I 4,2200 8.900 38 5.128.286
2022-01-31 2022-01-27 4 Peyer James SNSE Common Stock P - Purchase I 4,3100 6.100 26 5.119.386
2022-01-27 2022-01-26 4 Peyer James SNSE Common Stock P - Purchase I 4,6200 29.900 138 5.113.286
2022-01-27 2022-01-25 4 Peyer James SNSE Common Stock P - Purchase I 4,8600 20.100 98 5.083.386
2022-01-27 2022-01-26 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,6200 29.900 138 5.113.286
2022-01-27 2022-01-25 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,8600 20.100 98 5.083.386
2022-01-25 2022-01-24 4 Peyer James SNSE Common Stock P - Purchase I 4,6900 22.707 106 5.063.286
2022-01-25 2022-01-21 4 Peyer James SNSE Common Stock P - Purchase I 4,9400 24.703 122 5.040.579
2022-01-25 2022-01-24 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,6900 22.707 106 5.063.286
2022-01-25 2022-01-21 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,9400 24.703 122 5.040.579
2022-01-21 2022-01-20 4 Peyer James SNSE Common Stock P - Purchase I 5,1700 20.000 103 5.015.876
2022-01-21 2022-01-19 4 Peyer James SNSE Common Stock P - Purchase I 4,9700 10.244 51 4.995.876
2022-01-21 2022-01-20 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,1700 20.000 103 5.015.876
2022-01-21 2022-01-19 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,9700 10.244 51 4.995.876
2022-01-20 2022-01-18 4 Peyer James SNSE Common Stock P - Purchase I 5,0800 10.000 51 4.985.632
2022-01-20 2022-01-18 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,0800 10.000 51 4.985.632
2022-01-18 2022-01-14 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,9900 6.219 31 4.975.632
2022-01-18 2022-01-13 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,1300 19.953 102 4.969.413
2022-01-18 2022-01-14 4 Peyer James SNSE Common Stock P - Purchase I 4,9900 6.219 31 4.975.632
2022-01-18 2022-01-13 4 Peyer James SNSE Common Stock P - Purchase I 5,1300 19.953 102 4.969.413
2022-01-13 2022-01-12 4 Peyer James SNSE Common Stock P - Purchase I 5,2200 9.202 48 4.949.460
2022-01-13 2022-01-11 4 Peyer James SNSE Common Stock P - Purchase I 5,1800 10.845 56 4.940.258
2022-01-13 2022-01-12 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,2200 9.202 48 4.949.460
2022-01-13 2022-01-11 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,1800 10.845 56 4.940.258
2022-01-11 2022-01-10 4 Peyer James SNSE Common Stock P - Purchase I 5,2800 10.000 53 4.929.413
2022-01-11 2022-01-10 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,2800 10.000 53 4.929.413
2022-01-03 2021-12-30 4 Peyer James SNSE Common Stock P - Purchase I 4,8500 1.127 5 4.919.413
2022-01-03 2021-12-30 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,8500 1.127 5 4.919.413
2021-12-30 2021-12-29 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 4,9800 69.000 344 4.918.286
2021-12-30 2021-12-29 4 Peyer James SNSE Common Stock P - Purchase I 4,9800 69.000 344 4.918.286
2021-12-29 2021-12-28 4 Peyer James SNSE Common Stock P - Purchase I 5,2800 11.288 60 4.849.286
2021-12-29 2021-12-28 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,2800 11.288 60 4.849.286
2021-12-27 2021-12-27 4 Peyer James SNSE Common Stock P - Purchase I 5,3000 3.712 20 4.837.998
2021-12-27 2021-12-27 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,3000 3.712 20 4.837.998
2021-12-23 2021-12-23 4 Peyer James SNSE Common Stock P - Purchase I 5,2700 11.000 58 4.834.286
2021-12-23 2021-12-23 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,2700 11.000 58 4.834.286
2021-12-21 2021-12-17 4 Peyer James SNSE Common Stock P - Purchase I 5,2900 117 1 4.823.286
2021-12-21 2021-12-17 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,2900 117 1 4.823.286
2021-12-20 2021-12-16 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 5,2500 10.925 57 4.823.169
2021-12-20 2021-12-16 4 Peyer James SNSE Common Stock P - Purchase I 5,2500 10.925 57 4.823.169
2021-12-13 2021-12-10 4 RICKS THOMAS G SNSE Common Stock P - Purchase I 5,8600 20.000 117 341.769
2021-12-13 2021-12-09 4 RICKS THOMAS G SNSE Common Stock P - Purchase I 6,6200 20.000 132 321.769
2021-08-12 2021-08-11 4 Pierce Robert Hamilton By spouse SNSE Common Stock S - Sale I 7,3436 -16.030 -118 0
2021-08-10 2021-08-10 4 Pierce Robert Hamilton By spouse SNSE Common Stock S - Sale I 7,1289 -66.350 -473 16.030
2021-08-10 2021-08-09 4 Pierce Robert Hamilton By spouse SNSE Common Stock S - Sale I 7,0603 -6.982 -49 82.380
2021-08-10 2021-08-06 4 Pierce Robert Hamilton By spouse SNSE Common Stock S - Sale I 7,1127 -6.460 -46 89.362
2021-08-10 3/A Pierce Robert Hamilton By spouse SNSE Common Stock I 95.822
2021-08-02 2021-07-30 4 Humer Kristian SNSE Stock Option (Right to Buy) A - Award D 7,89 16.667 16.667
2021-05-06 2021-05-05 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 12,0000 350 4 4.812.244
2021-05-06 2021-05-05 4 Peyer James SNSE Common Stock P - Purchase I 12,0000 350 4 4.812.244
2021-04-21 2021-04-20 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 12,7700 385 5 4.811.894
2021-04-21 2021-04-20 4 Peyer James SNSE Common Stock P - Purchase I 12,7700 385 5 4.811.894
2021-04-20 2021-04-19 4 Peyer James SNSE Common Stock P - Purchase I 13,3800 1.965 26 4.811.509
2021-04-20 2021-04-19 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 13,3800 1.965 26 4.811.509
2021-04-14 2021-04-13 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 14,0000 2.000 28 4.809.544
2021-04-14 2021-04-13 4 Peyer James SNSE Common Stock P - Purchase I 14,0000 2.000 28 4.809.544
2021-04-08 2021-04-07 4 Peyer James SNSE Common Stock P - Purchase I 14,0000 2.000 28 4.807.544
2021-04-08 2021-04-07 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 14,0000 2.000 28 4.807.544
2021-04-05 2021-04-01 4 English Jessie SNSE Stock Option (Right to Buy) A - Award D 14,42 16.667 16.667
2021-04-02 2021-04-01 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 14,0000 1.000 14 4.805.544
2021-04-02 2021-04-01 4 Peyer James SNSE Common Stock P - Purchase I 14,0000 1.000 14 4.805.544
2021-03-31 2021-03-30 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 12,0000 2.000 24 4.804.544
2021-03-31 2021-03-30 4 Peyer James SNSE Common Stock P - Purchase I 12,0000 2.000 24 4.804.544
2021-03-25 2021-03-24 4 Peyer James SNSE Common Stock P - Purchase I 14,1200 3.750 53 4.802.544
2021-03-25 2021-03-24 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 14,1200 3.750 53 4.802.544
2021-03-24 2021-03-23 4 Peyer James SNSE Common Stock P - Purchase I 14,3400 10.000 143 4.798.794
2021-03-24 2021-03-23 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 14,3400 10.000 143 4.798.794
2021-03-23 2021-03-22 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 15,0200 2.183 33 4.788.794
2021-03-23 2021-03-22 4 Peyer James SNSE Common Stock P - Purchase I 15,0200 2.183 33 4.788.794
2021-03-19 2021-03-18 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 15,2500 817 12 4.786.611
2021-03-19 2021-03-18 4 Peyer James SNSE Common Stock P - Purchase I 15,2500 817 12 4.786.611
2021-03-10 2021-03-08 4 Peyer James SNSE Common Stock P - Purchase I 15,2490 1.000 15 4.785.794
2021-03-10 2021-03-08 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 15,2490 1.000 15 4.785.794
2021-03-08 2021-03-05 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 13,7500 8.000 110 4.784.794
2021-03-08 2021-03-05 4 Peyer James SNSE Common Stock P - Purchase I 13,7500 8.000 110 4.784.794
2021-03-05 2021-03-04 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 14,1250 2.000 28 4.776.794
2021-03-05 2021-03-03 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 15,8500 3.000 48 4.774.794
2021-03-05 2021-03-04 4 Peyer James SNSE Common Stock P - Purchase I 14,1250 2.000 28 4.776.794
2021-03-05 2021-03-03 4 Peyer James SNSE Common Stock P - Purchase I 15,8500 3.000 48 4.774.794
2021-03-03 2021-03-02 4 Peyer James SNSE Common Stock P - Purchase I 16,2500 3.000 49 4.771.794
2021-03-03 2021-03-02 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 16,2500 3.000 49 4.771.794
2021-03-02 2021-02-26 4 Peyer James SNSE Common Stock P - Purchase I 16,2500 5.000 81 4.768.794
2021-03-02 2021-02-26 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 16,2500 5.000 81 4.768.794
2021-02-26 2021-02-25 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 15,7900 12.000 189 4.763.794
2021-02-26 2021-02-24 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 18,4200 900 17 4.751.794
2021-02-26 2021-02-24 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 16,8400 18.100 305 4.750.894
2021-02-26 2021-02-25 4 Peyer James SNSE Common Stock P - Purchase I 15,7900 12.000 189 4.763.794
2021-02-26 2021-02-24 4 Peyer James SNSE Common Stock P - Purchase I 18,4200 900 17 4.751.794
2021-02-26 2021-02-24 4 Peyer James SNSE Common Stock P - Purchase I 16,8400 18.100 305 4.750.894
2021-02-25 2021-02-23 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 18,1000 14.300 259 4.732.794
2021-02-25 2021-02-23 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 17,0400 6.000 102 4.718.494
2021-02-25 2021-02-23 4 Peyer James SNSE Common Stock P - Purchase I 18,1000 14.300 259 4.732.794
2021-02-25 2021-02-23 4 Peyer James SNSE Common Stock P - Purchase I 17,0400 6.000 102 4.718.494
2021-02-24 2021-02-22 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 18,8800 9.802 185 4.712.494
2021-02-24 2021-02-22 4 Peyer James SNSE Common Stock P - Purchase I 18,8800 9.802 185 4.712.494
2021-02-23 2021-02-19 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 19,7700 11.786 233 4.702.692
2021-02-23 2021-02-19 4 Peyer James SNSE Common Stock P - Purchase I 19,7700 11.786 233 4.702.692
2021-02-19 2021-02-18 4 Peyer James SNSE Common Stock P - Purchase I 19,7500 753 15 4.690.906
2021-02-19 2021-02-18 4 Cambrian BioPharma Inc SNSE Common Stock P - Purchase D 19,7500 753 15 4.690.906
2021-02-10 2021-02-08 4 RICKS THOMAS G SNSE Series BB Preferred Convertible Stock C - Conversion I -3.037.849 0
2021-02-10 2021-02-08 4 RICKS THOMAS G SNSE Series AA Preferred Convertible Stock C - Conversion I -11.447.156 0
2021-02-10 2021-02-08 4 RICKS THOMAS G SNSE Common Stock C - Conversion I 301.769 301.769
2021-02-10 2021-02-08 4 Peyer James See footnotes SNSE Series BB Preferred Convertible Stock C - Conversion I -4.821.996 0
2021-02-10 2021-02-08 4 Peyer James SNSE Series AA Preferred Convertible Stock C - Conversion I -110.729.827 0
2021-02-10 2021-02-08 4 Peyer James SNSE Common Stock C - Conversion I 2.407.328 4.690.153
2021-02-10 2021-02-08 4 H&S INVESTMENTS I LP SNSE Series AA Convertible Preferred Stock C - Conversion D -209.368.245 0
2021-02-10 2021-02-08 4 H&S INVESTMENTS I LP SNSE Common Stock C - Conversion D 4.361.835 4.425.998
2021-02-10 2021-02-08 4 Cambrian BioPharma Inc SNSE Series BB Preferred Convertible Stock C - Conversion D -4.821.996 0
2021-02-10 2021-02-08 4 Cambrian BioPharma Inc SNSE Series AA Preferred Convertible Stock P - Purchase D -110.729.827 0
2021-02-10 2021-02-08 4 Cambrian BioPharma Inc SNSE Common Stock C - Conversion D 2.407.328 4.690.153
2021-02-05 2021-02-03 4 Vojta Deneen SNSE Stock Option (Right to Buy) A - Award D 19,00 16.666 16.666
2021-02-05 2021-02-03 4 RICKS THOMAS G SNSE Stock Option (Right to Buy) A - Award D 19,00 16.666 16.666
2021-02-05 2021-02-03 4 Holmen Bob SNSE Stock Option (Right to Buy) A - Award D 19,00 16.666 16.666
2021-02-05 2021-02-03 4 Peyer James SNSE Stock Option (Right to Buy) A - Award I 19,00 16.666 16.666
2021-02-05 2021-02-03 4 Fjaellskog Marie-Louise SNSE Stock Option (Right to Buy) A - Award D 19,00 79.166 79.166
2021-02-05 2021-02-03 4 Hoey Anupama SNSE Stock Option (Right to Buy) A - Award D 19,00 83.333 83.333
2021-02-05 2021-02-03 4 Colgan Erin SNSE Stock Option (Right to Buy) A - Award D 19,00 52.083 52.083
2021-02-05 2021-02-03 4 Celebi John SNSE Stock Option (Right to Buy) A - Award D 19,00 416.666 416.666
2021-02-05 2021-02-03 4 Broder Samuel SNSE Stock Option (Right to Buy) A - Award D 19,00 16.666 16.666
2021-02-05 2021-02-03 4 Cambrian BioPharma Inc SNSE Stock Option (Right to Buy) A - Award D 19,00 16.666 16.666
2021-02-03 3 Pierce Robert Hamilton SNSE Common Stock D 73.463
2021-02-03 3 Holmen Bob SNSE Common Stock D 16.666
2021-02-03 3 Peyer James SNSE Common Stock I 2.282.825
2021-02-03 3 SAMUELI SUSAN SNSE Common Stock D 64.163
2021-02-03 3 Cambrian BioPharma Inc SNSE Common Stock D 2.282.825
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
How Much do you Like Fintel?
Please share your opinion of our service!
Excellent Bad
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista